Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekBioPharma Dive ↗
The pharma hasn't yet revealed what kind of job cuts might be involved in the plan, which will help it absorb …
The WeekPharmaVoice ↗
Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could crea…
The WeekPharmaVoice ↗
Nearly one-third of prescriptions included in a new study were rejected the first time a patient attempted to …
The WeekFiercePharma ↗
Havas Lynx has shaken up the leadership of its New York team, expanding Claire Knapp's role to cover the offic…
The WeekFierceBiotech ↗
Rare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research…
The WeekBriefing
FDA approval of Otsuka’s Simtriyo gives the company a first-in-class ADHD asset. The real question now is whet…
The WeekDrug Channels ↗
By Bryce Platt, PharmD Summer's in full swing, but the drug channel didn't take a break. What better way to sp…
The WeekSTAT News ↗
ProMIS Neurosciences is trying to design a safer amyloid-clearing drug for Alzheimer's. Early results suggest …
The WeekBioPharma Dive ↗
Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not co…
The WeekPharmaVoice ↗
Startups like Altos Labs are keeping pipeline details scarce to protect their ideas from competitors - but som…
The WeekFiercePharma ↗
Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is strugglin…
The WeekFierceBiotech ↗
Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease …
The WeekBriefing
Nuvalent’s Jideytro won FDA approval for adults with locally advanced or metastatic ROS1-positive NSCLC after …
The WeekBioPharma Dive ↗
How can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026.…
The WeekSTAT News ↗
"Emergency departments across America report dramatic increases in serious injuries from e-bikes and e-scooter…
The WeekFiercePharma ↗
As outside experts gathered for a second day to discuss adding certain popular-yet-unapproved peptides to the …
The WeekFierceBiotech ↗
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial tea…
The WeekBriefing
Three items stood out this week: U.S. import tariffs on generic drugs, Samsung Biologics pursuing a $1.8 billi…
The WeekFiercePharma ↗
A survey of 36 U.S. gastroenterologists found that significant treatment gaps remain in the growing IBD drug m…
The WeekFierceBiotech ↗
Amgen has laid off around 40 employees as part of "organizational changes" meant to better align operations wi…
The WeekSTAT News ↗
"Consumers should not be faced with a trade-off between nutrition and food safety," writes Susan Mayne, former…
The WeekSTAT News ↗
Robert F. Kennedy Jr. has lauded peptides and said he takes them himself.…
The WeekBioPharma Dive ↗
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a …
The WeekPharmaVoice ↗
High-level turnover has introduced uncertainty about how quickly the FDA's agency-wide AI strategy will move f…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.